BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 26614029)

  • 1. Emerging Bladder Cancer Biomarkers and Targets of Therapy.
    Netto GJ; Tafe LJ
    Urol Clin North Am; 2016 Feb; 43(1):63-76. PubMed ID: 26614029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.
    Mbeutcha A; Lucca I; Mathieu R; Lotan Y; Shariat SF
    Urol Clin North Am; 2016 Feb; 43(1):47-62. PubMed ID: 26614028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in the Diagnosis and Management of Bladder Cancer.
    Zhang X; Han C; He J
    Cell Biochem Biophys; 2015 Sep; 73(1):11-5. PubMed ID: 25716337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
    Kim YJ; Kim WJ
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S77-88. PubMed ID: 27326410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
    McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer.
    Zhang H; Fan Y; Xia L; Gao C; Tong X; Wang H; Sun L; Ji T; Jin M; Gu B; Fan B
    Tumour Biol; 2017 Mar; 39(3):1010428317691183. PubMed ID: 28345451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive approaches for detecting and monitoring bladder cancer.
    Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):283-94. PubMed ID: 25494295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
    Mikhailenko DS; Nemtsova MV
    Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond.
    Mitra AP; Lerner SP
    Urol Clin North Am; 2015 May; 42(2):201-15, viii. PubMed ID: 25882562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
    van der Kwast TH; Bapat B
    Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of urothelial carcinoma: the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer.
    Lacy S; Lopez-Beltran A; MacLennan GT; Foster SR; Montironi R; Cheng L
    Anal Quant Cytol Histol; 2009 Feb; 31(1):5-16. PubMed ID: 19320188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.
    Weikert S; Christoph F; Schrader M; Krause H; Miller K; Müller M
    Int J Cancer; 2005 Aug; 116(1):100-4. PubMed ID: 15761870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
    Jones RT; Felsenstein KM; Theodorescu D
    Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine and Serum Exosomes as Novel Biomarkers in Detection of Bladder Cancer.
    Elsharkawi F; Elsabah M; Shabayek M; Khaled H
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2219-2224. PubMed ID: 31350988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
    Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
    J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
    Grivas PD; Melas M; Papavassiliou AG
    Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of extracellular vesicles as biomarkers for urogenital cancers.
    Nawaz M; Camussi G; Valadi H; Nazarenko I; Ekström K; Wang X; Principe S; Shah N; Ashraf NM; Fatima F; Neder L; Kislinger T
    Nat Rev Urol; 2014 Dec; 11(12):688-701. PubMed ID: 25403245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.
    Shi S; Tian B
    Cancer Biomark; 2019; 24(2):183-193. PubMed ID: 30689556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
    Jin N; Jin X; Gu X; Na W; Zhang M; Zhao R
    Mol Med Rep; 2015 Aug; 12(2):3170-6. PubMed ID: 25955758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.